

Pyk2(Phospho-Tyr402) Antibody

Catalog No: #11216

Package Size: #11216-1 50ul #11216-2 100ul

Description

Product Name	Pyk2(Phospho-Tyr402) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB IHC IF
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous level of Pyk2 only when phosphorylated at tyrosine 402.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 402 (D-I-Y(p)-A-E) derived from Human Pyk2.
Conjugates	Unconjugated
Target Name	Pyk2
Modification	Phospho
Other Names	FADK 2; FAK2; Focal adhesion kinase 2; PTK2B; Proline-rich tyrosine kinase 2 RAFTK
Accession No.	Swiss-Prot: Q14289NCBI Protein: NP_004094.3
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details


Predicted MW: 116kd

Western blotting: 1:500~1:1000


Immunohistochemistry: 1:50~1:100

Immunofluorescence: 1:100~1:200


Images



Western blot analysis of extracts from 293 cells untreated or treated with Serum using Pyk2(Phospho-Tyr402) Antibody #11216.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Pyk2(Phospho-Tyr402) Antibody #11216(left) or the same antibody preincubated with blocking peptide(right).



Immunofluorescence staining of methanol-fixed HeLa cells using Pyk2(Phospho-Tyr402) Antibody #11216.

Background

Involved in calcium induced regulation of ion channel and activation of the map kinase signaling pathway. May represent an important signaling intermediate between neuropeptide activated receptors or neurotransmitters that increase calcium flux and the downstream signals that regulate neuronal activity. Interacts with the SH2 domain of Grb2. May phosphorylate the voltage-gated potassium channel protein Kv1.2. Its activation is highly correlated with the stimulation of c-Jun N-terminal kinase activity. Involved in osmotic stress-dependent SNCA 'Tyr-125' phosphorylation.

Gluck SL, et al. (2004) J Clin Invest; 114(12): 1696-1699

Benzing T, et al. (2001) Proc Natl Acad Sci U S A; 98(17): 9784-9789

Tian D, et al. (2002) Mol Cell Biol; 22(8): 2650-2662

Lu Z, et al. (2001) Mol Cell Biol; 21(12): 4016-4031

Krishnan HH, et al. (2006) J Virol; 80(3): 1167-1180

Published Papers

Mineko Tomomura, Hiroya Hasegawa, Naoto Suda et al., Serum Calcium-decreasing Factor, Caldecrin, Inhibits Receptor Activator of NF- B Ligand (RANKL)-mediated Ca²⁺ Signaling and Actin Ring Formation in Mature Osteoclasts via Suppression of Src Signaling Pathway., THE JOURNAL OF BIOLOGICAL CHEMISTRY, 287(22):17963-17974.(2012)

PMID:22461633

et al., Serum Calcium-decreasing Factor, Caldecrin, Inhibits Receptor Activator of NF- κ B Ligand (RANKL)-mediated Ca²⁺ Signaling and Actin Ring Formation in Mature Osteoclasts via Suppression of Src Signaling Pathway. In J Biol Chem on 2012 May 25 by Mineko Tomomura, Hiroya Hasegawa, et al..PMID:22461633, , (2012)

[PMID:22461633](#)

et al., Potential Involvement of M1 Macrophage and VLA4/VCAM-1 Pathway in the Valvular Damage Due to Rheumatic Heart Disease. In Front Biosci (Landmark Ed) on 2024 Jun 18 by Shenglin Xian, Yuan Li,et al..PMID:38940032, , (2024)

[PMID:38940032](#)

Yuwen Sheng;Chong Qiao;Zhonghui Zhang;Xiaoke Shi;Linhan Yang;Ruiying Xi;Jialing Yu;Wanli Liu;Guolin Zhang;Fei Wang et al., Calcium Channel Blocker Lacidipine Promotes Antitumor Immunity by Reprogramming Tryptophan Metabolism., , (2025)

[PMID:39585774](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.